Related Experiment Videos
Monoamines, depression and antidepressant drugs
1Maudsley Hospital, London, U.K.
Pharmacopsychiatry
|January 1, 1988
Summary
Noradrenergic pathways regulate melatonin secretion. Antidepressant effects on melatonin levels differ between rats and humans, suggesting distinct mechanisms and supporting the role of increased monoamine transmission in treating depression.
Area of Science:
- Neuroscience
- Pharmacology
- Endocrinology
Background:
- Noradrenergic systems centrally control melatonin secretion.
- The pineal gland serves as a model to study noradrenergic transmission.
- Melatonin levels reflect changes in noradrenergic activity.
Purpose of the Study:
- To investigate the noradrenergic control of melatonin secretion.
- To compare the effects of antidepressants on melatonin levels in rats and humans.
- To explore the neurobiological underpinnings of depression and antidepressant action.
Main Methods:
- Monitoring plasma melatonin levels to assess noradrenergic transmission.
- Evaluating the impact of chronic imipramine treatment on rat pineal adrenoreceptor binding and melatonin.
- Analyzing the effects of chronic desipramine treatment on plasma melatonin levels in depressed patients.
Main Results:
- Chronic imipramine reduced adrenoreceptor binding and melatonin in rats.
- Chronic desipramine increased plasma melatonin levels in depressed patients.
- Data support antidepressants increasing monoamine transmission in humans.
Conclusions:
- Noradrenergic control of melatonin secretion is consistent with central noradrenergic systems.
- Antidepressant mechanisms in humans may involve increasing monoamine transmission.
- A potential hypothalamic neuropeptide modulated by antidepressants is postulated for depression.